The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Abbott Diabetes (I); Novartis
Stock and Other Ownership Interests - Jounce Therapeutics; Novartis
Travel, Accommodations, Expenses - Novartis
CANOPY-A: A phase III, multicenter, randomized, double-blind, placebo-controlled trial evaluating canakinumab as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC).
 
Edward B. Garon
Consulting or Advisory Role - Dracen; EMD Serono; GlaxoSmithKline; Novartis
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Genentech (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst)
 
Andrea Ardizzoni
Honoraria - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD; Roche
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Roche (Inst)
 
Fabrice Barlesi
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Pierre Fabre; Takeda
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Innate Pharma (Inst); Ipsen (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb; MSD Oncology; Roche/Genentech
 
Byoung Chul Cho
Stock and Other Ownership Interests - Bridgebio; Gencurix; Theravance
Honoraria - AstraZeneca; Bayer; Champions Oncology; Dizal Pharma; Dong-A ST; Janssen; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda; Yuhan
Speakers' Bureau - Novartis
Research Funding - AstraZeneca; Bayer; Champions Oncology; Dizal Pharma; Dong-A ST; Janssen; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan
Patents, Royalties, Other Intellectual Property - Champions Oncology
 
Pedro De Marchi
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; MSD; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Bayer; Bristol-Myers Squibb; MSD; Pfizer; Roche
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD; Roche
 
Yasushi Goto
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Pfizer; Shionogi; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; GlaxoSmithKline; Illumina; Kyorin; Lilly; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); EPS Holdings (Inst); Genomic Health (Inst); IQvia (Inst); Kyorin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Dariusz M. Kowalski
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck; MSD; Pfizer; Roche/Genentech
 
Shun Lu
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Hutchison MediPharma; Roche; Simcere
Speakers' Bureau - AstraZeneca; Hansoh; Roche
Research Funding - AstraZeneca; Bristol-Myers Squibb; HenRui; Hutchison MediPharma; Roche
 
Luis G. Paz-Ares
Leadership - Altum Sequencing; European Medicines Agency (I); Genomica
Honoraria - Advanced Accelerator Applications; Amgen; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Incyte; Ipsen; Lilly; Merck Serono; MSD; Novartis; Pfizer; PharmaMar; Roche/Genentech; Sanofi; Servier; Sysmex
Research Funding - AstraZeneca; Bristol-Myers Squibb
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD; Pfizer; Roche; Takeda
Other Relationship - Amgen (I); Ipsen (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)
 
David R. Spigel
Leadership - TriStar Centennial Medical Center
Consulting or Advisory Role - Aptitude Health (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Dracen (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Iksuda Therapeutics (Inst); Illumina (Inst); Merck (Inst); Molecular Templates (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Seagen (Inst); Takeda (Inst); TRIPTYCH Health Partners (Inst); TRM Oncology (Inst); Williams and Connolly (Inst)
Research Funding - Aeglea Biotherapeutics (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BIND Therapeutics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); GRAIL (Inst); ImClone Systems (Inst); Immunogen (Inst); Ipsen (Inst); Janssen Oncology (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Molecular Partners (Inst); Nektar (Inst); Neon Therapeutics (Inst); Novartis (Inst); Takeda (Inst); Transgene (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Genentech; GlaxoSmithKline; Janssen Oncology; Merck; Novartis; Pfizer; Seagen; Spectrum Pharmaceuticals; Takeda
 
Alexander I. Spira
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; CytomX Therapeutics; Merck; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); incyte; Novartis
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); Arch Therapeutics (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novartis (Inst); Plexxikon (Inst); Roche (Inst); Takeda (Inst); Trovagene (Inst)
 
Michael Thomas
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Lilly; MSD; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Janssen; Lilly; MSD; Novartis; Pfizer; Roche; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; MSD; Novartis; Pfizer; Roche; Takeda
 
Mimi Leung
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Jason Baum
No Relationships to Disclose
 
Zewen Zhu
Employment - Novartis
 
Maria do Socorro Oliveira Portella
Employment - Novartis
 
James Chih-Hsin Yang
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Amgen; Astellas Pharma; AstraZeneca; AstraZeneca (Inst); Bayer; Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo; G1 Therapeutics; Hansoh; Incyte; Lilly; Merck Serono; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Roche/Genentech; Takeda; Yuhan
Travel, Accommodations, Expenses - Pfizer